7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma
Source: Oncology Nursing News, July 2022
At a 7.5-year follow-up, nivolumab (Opdivo)-based treatment regimens continued to display superior overall survival (OS) rates, duration of response (DOR), and health-related quality of life (HRQOL) compared with ipilimumab (Yervoy) monotherapy, according to a long-term follow-up analysis of CheckMate 067 (NCT01844505) presented during the 2022 ASCO Annual Meeting.
In the trial, 314 patients received nivolumab/ipilimumab, 316 received nivolumab alone, and 315 received ipilimumab alone. The OS survival rate among those receiving dual immunotherapy was 48% compared with 42% with nivolumab alone and 22% ipilimumab alone. The median OS in these groups was 72.1 months (95% CI, 38.2-not reached [NR]), 26.9 months (95% CI, 28.2-58.7), and 19.9 months (95% CI, 16.8-24.6), respectively.
The progression-free survival (PFS) rate among the 3 cohorts was 37%, 36%, and 33%, respectively. Median PFS was 11.5 months (95% CI, 8.9-10.0), 6.9 months (95% CI, 5.1-10.2), and 2.9 months (95% CI, 2.8-3.1).